Induction of “Cytokine storm” in patients infected with SARS-CoV-2 and development of COVID-19. Does the gastrointestinal tract any relation in severity?
DOI:
https://doi.org/10.22516/25007440.539Keywords:
SARS Virus, COVID-19, Coronavirus, Cytokines, gastrointestinal tractAbstract
Coronaviruses are an extensive family of viruses, some of them can produce different kind of human diseases, ranging from the common cold to severe acute respiratory syndrome. Coronavirus disease (COVID-19) is caused by the SARS-CoV-2 zoonotic coronavirus and started in China in December 2019. In March 2020, the World Health Organization (WHO) declared it a global pandemic. This disease has a wide spectrum of signs and symptoms, predominantly presenting with cough and fever, resulting in a proportion of patients who develop acute respiratory distress syndrome (ARDS). It has been argued that severe lung involvement by the virus may also be caused by hyperinflammation and a condition similar to hemophagocytic lymphohistiocytosis (HLH), which is a clinical syndrome caused by an inadequate response of the immune system to a trigger, whether infectious, neoplastic, metabolic, or rheumatologic, leading to a disproportionate inflammatory reaction. This activated immune response producing an exaggerated release or storm of cytokines responsible for this disease. There are recently publications suggesting that the presence of gastrointestinal symptoms is associated with COVID 19 disease with higher indicators of severity, which motivates the gastroenterologist to explore how the digestive system could impact this hyperinflammation.
Downloads
References
WHO [Internet]. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. 2020 [citado 31 de marzo de 2020]. Disponible en: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020. https://doi.org/10.1053/j.gastro.2020.02.054
Cascella M, Rajnik M, Cuomo A, et al. Features, Evaluation and Treatment Corona-virus (COVID-19) [actualizado 6 de abril de 2020]. En: StatPearls [Internet]. Treasure Is-land (FL): StatPearls Publishing; 2020. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK554776/
Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal In-fection of SARS-CoV-2. Gastroenterology. 2020. pii: S0016-5085(20)30282-1. https://doi.org/10.1053/j.gastro.2020.02.055
Davenne E, Giot JB, Huynen P. [Coronavirus and COVID-19 : focus on a galop-ping pandemic]. Rev Med Liege. 2020;75(4):218-225.
Dapena Díaz JL, Díaz de Heredia Rubio C, Bastida Vila P, Llort Sales A, Elorza Alvarez I, Olivé Oliveras T, et al. [Haemophagocytic syndrome: A common pathogenic mechanism of various aetiologies]. An Pediatr (Barc). 2009;71(2):110-6. https://doi.org/10.1016/j.anpedi.2009.04.008
Buda P, Gietka P, Wieteska-Klimczak A, Ksiazyk J. [Secondary hemophagocytic syndromes]. Wiad Lek. 2013;66(2 Pt 2):153-63.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma inflammato-ry cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95-103. https://doi.org/10.1111/j.1365-2249.2004.02415.x
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0
Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16-32. https://doi.org/10.1128/MMBR.05015-11
Makhija R, Kingsnorth AN. Cytokine storm in acute pancreatitis. J Hepatobiliary Pancreat Surg. 2002;9(4):401-10. https://doi.org/10.1007/s005340200049
Ferrara JL. Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol. 1993;5(5):794-9. https://doi.org/10.1016/0952-7915(93)90139-j
Barton GM. A calculated response: control of inflammation by the innate immune system. J Clin Invest. 2008;118(2):413-20. https://doi.org/10.1172/JCI34431
D›Elia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC. Targeting the «cy-tokine storm» for therapeutic benefit. Clin Vaccine Immunol. 2013;20(3):319-27. https://doi.org/10.1128/CVI.00636-12
Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infec-tious diseases. Blood. 2000;95(10):3032-43.
Kritas SK, Ronconi G, Caraffa A, Gallenga CE, Ross R, Conti P. Mast cells con-tribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J Biol Regul Homeost Agents. 2020;34(1). https://doi.org/10.23812/20-Editorial-Kritas
Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020 Mar 14;34(2). pii: 1. https://doi.org/10.23812/CONTI-E
Marchetti C, Swartzwelter B, Koenders MI, Azam T, Tengesdal IW, Powers N, et al. NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine mod-els of acute arthritis. Arthritis Res Ther. 2018;20(1):169. https://doi.org/10.1186/s13075-018-1664-2
Us D. [Cytokine storm in avian influenza]. Mikrobiyol Bul. 2008;42(2):365-80.
Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018;104:8-13. https://doi.org/10.1016/j.cyto.2018.01.025
Fowler AA, Fisher BJ, Centor RM, Carchman RA. Development of the adult respir-atory distress syndrome: progressive alteration of neutrophil chemotactic and secretory pro-cesses. Am J Pathol. 1984;116(3):427-35.
Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med. 2001;163(2):316-21. https://doi.org/10.1164/ajrccm.163.2.2007102
Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Devel-opment and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-20. https://doi.org/10.1002/art.38690.
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020. https://doi.org/10.1007/s00134-020-05991-x
Zheng F, Liao C, Fan QH, Chen HB, Zhao XG, Xie ZG, et al. Clinical Characteris-tics of Children with Coronavirus Disease 2019 in Hubei, China. Curr Med Sci. 2020;40(2):275-280. https://doi.org/10.1007/s11596-020-2172-6
Shimizu K, Ogura H, Hamasaki T, Goto M, Tasaki O, Asahara T, et al. Altered gut flora are associated with septic complications and death in critically ill patients with systemic inflammatory response syndrome. Dig Dis Sci. 2011;56(4):1171-7. https://doi.org/10.1007/s10620-010-1418-8
Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011;91(1):151-75. https://doi.org/10.1152/physrev.00003.2008
Salvo-Romero E, Cotoner M del CA, Camacho CP, Casado-Bedmar M, Vicario M. Función barrera intestinal y su implicación en enfermedades digestivas. Rev Esp Enferm Dig. 2015;107(11):686-96.
Cheung KS, Hung IF, Chan PP, Lung KC, Tso E, Liu R, et al. Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis. Gastroenterology. 2020. pii:S0016-5085(20)30448-0. https://doi.org/10.1053/j.gastro.2020.03.065
Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020. pii: gutjnl-2020-320926. https://doi.org/10.1136/gutjnl-2020-320926
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473-475. https://doi.org/10.1016/S0140-6736(20)30317-2
Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Crit Care Med. 2016;44(2):275-81. https://doi.org./10.1097/CCM.0000000000001402
Chinese Clinical Trial Register (ChiCTR) [Internet]. The world health organization international clinical trials registered organization registered platform [citado 9 de abril de 2020]. Disponible en: http://www.chictr.org.cn/showprojen.aspx?proj=49409
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
